Abstract
Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have